skip to main |
skip to sidebar
Nordion in trouble?
Nordion in trouble? Nordion undertakes review of strategic options http://www.theglobeandmail.com/globe-investor/nordion-undertakes-review-of-strategic-options/article7919265/
"Nordion is one of the world’s leading producers of molybdenum-99,
used in medical imaging, and it depends on raw material from AECL’s
aging facility in Chalk River, Ont.
The plant has been operating
since 1957, and while it is licensed to operate until 2016, its future
beyond that is unclear. Nordion had hoped to force AECL to pay damages
or complete two new reactors that would have ensured a long-term supply
of the radioactive material it needs.
Nordion’s dispute with AECL
turns on the Maple reactors, built to replace Chalk River. The reactors
never worked properly, and AECL halted an effort to repair them in 2008.
Nordion has argued that AECL is legally required to complete the
reactors, or pay damages.
Despite the arbitration loss, it has not
given up that objective, and on Jan. 18 it returned to court, amending
its 2008 statement of claim against AECL in the Ontario Superior Court
of Justice to seek damages of $243.5-million for negligence and breach
of their production agreement.
Nordion has struggled to find an
alternative supplier. It terminated a preliminary agreement with a
subsidiary of Russia’s State Atomic Energy Corp. in October and said it
would begin talks with a related Russian source.
But even if the
negotiations result in a new deal, Nordion would obtain less material
than previously thought, the company said then.
Moly-99 is not
Nordion’s only product, and the company has said in the past that it
expects future growth to be driven by its “targeted therapies” business,
which includes TheraSphere, a liver cancer treatment. It also sells
sterilization systems that use radiation, and isotopes used in
sterilization. Those businesses do not depend on the Chalk River
facility.
Nordion took a $24.1-million charge related to the ongoing
litigation, and that, paired with higher income tax expenses, hurt its
fourth-quarter results, even as revenue edged higher.
For the
quarter to Oct. 31, it reported a loss of $43.5-million, or 70 cents a
share, compared with a profit of $6.9-million, or 11 cents, a year
earlier."
great!
ReplyDelete